In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.Read More
Breast cancer is the most commonly diagnosed cancer in the United States. In 2018, 266,120 women and 2,550 men are expected to receive the news that they have the disease, according to National Cancer Institute data.
Inherited mutations in the BRCA1 and BRCA2 genes account for between 5 percent and 10 percent of breast cancers in U.S. women and between 5 percent and 20 percent of breast cancers in U.S. men. For women who undergo genetic testing and learn that they have inherited a BRCA1/2 mutation before they receive a breast cancer diagnosis there are ways to reduce their risk of going on to develop the disease.Read More
In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015 that hold promise for combination cancer therapies, I discussed clinical trials …Read More
Just before the holidays, the U.S. Food and Drug Administration (FDA) had good news for the ovarian cancer research community when it announced the approval of both a personalized cancer …Read More